Lantus limbo

What Sanofi's Lantus rebates mean for new insulin candidates launching in 2015

The abrupt slowing of Lantus sales in the U.S. could augur reimbursement pressure for new insulin candidates entering the market from Sanofi and its competitors.

A halving of U.S. sales growth for Lantus insulin glargine in the third quarter compared with the prior year's growth rate is one of the reasons Sanofi's board said it removed CEO Christopher Viehbacher and put Chairman Serge Weinberg in his place while the pharma seeks a permanent replacement (see Cover Story).

Viehbacher attributed the bleeding to a requirement for increased rebates in the

Read the full 872 word article

How to gain access

Continue reading with a
two-week free trial.